The Role of Cardiac Biomarkers in the Diagnosis and Management of Patients Presenting with Suspected Acute Coronary Syndrome
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Myocardial infarction (MI) is the leading cause of death in the developed world. Biomarkers have an essential role in diagnosis, risk stratification, guiding management and clinical decision making in the setting of patients presenting with signs and symptoms of MI. Cardiac troponin (cTn) rose to prominence during the 1990s and has evolved to be the cornerstone for diagnosis of MI. The current criteria for MI diagnosis include a rise and/or fall in cTn with at least one value above the 99th percentile of the upper reference limit. Along with cTn, the natriuretic peptides B-type natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP) have an important role in determining prognosis and guiding management. As assays for cTn have been evolved that are capable of reliably detecting smaller and smaller quantities in the blood, a dilemma has emerged as to how to use this new information. Several studies have attempted to answer this question and have shown that these lower concentrations of cTn have important prognostic significance and, more importantly, that intervention in these patients leads to improved clinical outcomes. New algorithms incorporating BNP, NT-proBNP, and more sensitive cTn assays hold promise for more rapid diagnosis or rule-out of MI, allowing for appropriate management steps to be initiated and more efficient and effective utilization of healthcare resources
Abstract
Myocardial infarction (MI) is the leading cause of death in the developed world. Biomarkers have an essential role in diagnosis, risk stratification, guiding management and clinical decision making in the setting of patients presenting with signs and symptoms of MI. Cardiac troponin (cTn) rose to prominence during the 1990s and has evolved to be the cornerstone for diagnosis of MI. The current criteria for MI diagnosis include a rise and/or fall in cTn with at least one value above the 99th percentile of the upper reference limit. Along with cTn, the natriuretic peptides B-type natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP) have an important role in determining prognosis and guiding management. As assays for cTn have been evolved that are capable of reliably detecting smaller and smaller quantities in the blood, a dilemma has emerged as to how to use this new information. Several studies have attempted to answer this question and have shown that these lower concentrations of cTn have important prognostic significance and, more importantly, that intervention in these patients leads to improved clinical outcomes. New algorithms incorporating BNP, NT-proBNP, and more sensitive cTn assays hold promise for more rapid diagnosis or rule-out of MI, allowing for appropriate management steps to be initiated and more efficient and effective utilization of healthcare resources
참고문헌 (39)
- Lloyd-Jones D, "Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee", Circulation, 119, pp.480~486 (2009)
- Morrow DA, "National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes", Circulation, 115, pp.e356~e375 (2007)
- Thygesen K, "Third universal definition of myocardial infarction", J Am Coll Cardiol, 60, pp.1581~1598 (2012)
- Thygesen K, "Universal definition of myocardial infarction", J Am Coll Cardiol, 50, pp.2173~2195 (2007)
- Babuin L, "Troponin: the biomarker of choice for the detection of cardiac injury", CMAJ, 173, pp.1191~1202 (2005)
- Farah CS, "The troponin complex and regulation of muscle contraction", FASEB J, 9, pp.755~767 (1995)
- Wu AH, "Analytical and assay issues for use of cardiac troponin testing for risk stratification in primary care", Clin Biochem, 46, pp.969~978 (2013)
- Luepker RV, "Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute", Circulation, 108, pp.2543~2549 (2003)
- Wu AH, "Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases", Clin Chem, 41, pp.1228~1233 (1995)
- Heidenreich PA, "The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis", J Am Coll Cardiol, 38, pp.478~485 (2001)
- Kelley WE, "Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure", Clin Chem, 55, pp.2098~2112 (2009)
- Alpert JS, "Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology", American College of Cardiology Committee for the redefinition of myocardial infarction, 2000, pp.36, 959~969
- Newby LK, "ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents", J Am Coll Cardiol, 60, pp.2427~2463 (2012)
- "Nomenclature and criteria for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology", World Health Organization task force on standardization of clinical nomenclature, 1979, pp.59, 607~609
- Cummins P, "Troponin I from human skeletal and cardiac muscles", Biochem J, 171, pp.251~259 (1978)
- Wu AH, "National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases", Clin Chem, 45, pp.1101~1121 (1999)
- Panteghini M, "Evaluation of imprecision for cardiac troponin assays at low-range concentrations", Clin Chem, 50, pp.327~332 (2004)
- Apple FS, "National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biochemical markers of acute coronary syndromes", Clin Chem, 53, pp.547~551 (2007)
- Apple FS, "Analytical characteristics of high-sensitivity cardiac troponin assays", Clin Chem, 58, pp.54~61 (2012)
- Keller T, "Making it more sensitive: the new era of troponin use", Circulation, 123, pp.1361~1363 (2011)
- Melanson SE, "Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity", Am J Clin Pathol, 128, pp.282~286 (2007)
- Reichlin T, "Early diagnosis of myocardial infarction with sensitive cardiac troponin assays", N Engl J Med, 361, pp.858~867 (2009)
- Jesse RL, "On the relative value of an assay versus that of a test: a history of troponin for the diagnosis of myocardial infarction", J Am Coll Cardiol, 55, pp.2125~2128 (2010)
- Mills NL, "Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome", JAMA, 305, pp.1210~1216 (2011)
- Jeremias A, "Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded", Ann Intern Med, 142, pp.786~791 (2005)
- Wu AH, "Interpretation of high sensitivity cardiac troponin I results: reference to biological variability in patients who present to the emergency room with chest pain: case report series", Clin Chim Acta, 401, pp.170~174 (2009)
- Giannitsis E, "Highsensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission", Clin Chem, 56, pp.642~650 (2010)
- Casals G, "Impact of ultrasensitive cardiac troponin I dynamic changes in the new universal definition of myocardial infarction", Am J Clin Pathol, 130, pp.964~968 (2008)
- Apple FS, "Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events", Clin Chem, 55, pp.930~937 (2009)
- Reichlin T, "Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction", Circulation, 124, pp.136~145 (2011)
- Reichlin T, "One-hr rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T", Arch Intern Med, 172, pp.1211~1218 (2012)
- Riezebos RK, "The value of Nterminal proB-type natriuretic peptide for early identification of myocardial infarction in patients with high-risk non-ST-elevation acute coronary syndromes", Clin Chem Lab Med, 49, pp.1359~1365 (2011)
- Jernberg T, "Natriuretic peptides in unstable coronary artery disease", Eur Heart J, 25, pp.1486~1493 (2004)
- Ordonez-Llanos J, "Amino-terminal pro- B-type natriuretic peptide: analytic considerations", Am J Cardiol, 101, pp.9~15 (2008)
- Zeng X, "The prognostic value of N-terminal pro-brain natriuretic peptide in non-ST elevation acute coronary syndromes: a metaanalysis", Clin Chem Lab Med, 50, pp.731~739 (2012)
- Truong QA, "Multi-marker strategy of natriuretic peptide with either conventional or high-sensitivity troponin-T for acute coronary syndrome diagnosis in emergency department patients with chest pain: from the “Rule Out Myocardial Infarction using Computer Assisted Tomography” (ROMICAT) trial", Am Heart J, 163, pp.972~979.e1 (2012)
- Melki D, "Prognostic value of combining high sensitive troponin T and N-terminal pro B-type natriuretic peptide in chest pain patients with no persistent ST-elevation", Clin Chim Acta, 413, pp.933~937 (2012)
- Mathewkutty S, "Biomarkers after risk stratification in acute chest pain (from the BRIC Study)", Am J Cardiol, 111, pp.493~498 (2013)
- Scirica BM, "Association between Natriuretic Peptides and Mortality among Patients Admitted with Myocardial Infarction: a Report from the ACTION Registry(R)-GWTGTM", Clin Chem (2013)[DOI]